Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension
- PMID: 7894213
- DOI: 10.1007/BF00190742
Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension
Abstract
The nifedipine gastrointestinal therapeutic system (GITS) is a recently developed controlled-release formulation for once-a-day dosing. We evaluated the influence of morning versus evening administration of the drug in a randomized double-blind cross-over study including 15 essential hypertensives. Five patients had to be excluded from blood pressure analysis because of noncompliance (three cases) or intolerable side effects (two cases). To assess the exact duration of the antihypertensive efficacy noninvasive automatic ambulatory blood pressure monitoring was performed. After a placebo period patients were given 30 mg nifedipine GITS either at 1000 or 2200 hours. Twenty-four-hours systolic and diastolic blood pressure profiles documented a sustained antihypertensive effect of both nifedipine regimens throughout the whole period without affecting the circadian rhythm. Statistical analysis revealed no significant difference between morning and evening administration. Two patients stopped their medication because of intolerable side effects (fatigue and muscle cramps, respectively). Two more cases suffered from mild reversible headache which provoked no discontinuation of the drug. In conclusion our results document a sustained antihypertensive efficacy of 30 mg nifedipine GITS in patients with moderate essential hypertension. Time of administration has no impact on day- and nighttime blood pressure control.
Similar articles
-
The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group.Clin Ther. 1995 Jan-Feb;17(1):12-29. doi: 10.1016/0149-2918(95)80003-4. Clin Ther. 1995. PMID: 7758054 Clinical Trial.
-
Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.J Hypertens Suppl. 1994 Jul;12(5):S23-7. J Hypertens Suppl. 1994. PMID: 7965282 Clinical Trial.
-
Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg.Clin Ther. 2001 Jan;23(1):87-96. doi: 10.1016/s0149-2918(01)80032-1. Clin Ther. 2001. PMID: 11219482 Clinical Trial.
-
Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group.J Hypertens Suppl. 1994 Nov;12(8):S97-106. J Hypertens Suppl. 1994. PMID: 7707165 Review.
-
The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.Clin Pharmacokinet. 1996 Jan;30(1):28-51. doi: 10.2165/00003088-199630010-00003. Clin Pharmacokinet. 1996. PMID: 8846626 Review.
Cited by
-
Pharmacologic agents in the management of hypertension--nisoldipine coat-core.J Clin Hypertens (Greenwich). 2007 Apr;9(4):259-66. doi: 10.1111/j.1524-6175.2007.06628.x. J Clin Hypertens (Greenwich). 2007. PMID: 17396068 Free PMC article. Review.
-
Chronotherapeutics for cardiovascular disease.Drugs. 1998 May;55(5):631-43. doi: 10.2165/00003495-199855050-00003. Drugs. 1998. PMID: 9585861 Review.
-
Evening versus morning dosing regimen drug therapy for hypertension.Cochrane Database Syst Rev. 2024 Feb 14;2(2):CD004184. doi: 10.1002/14651858.CD004184.pub3. Cochrane Database Syst Rev. 2024. PMID: 38353289 Review.
-
Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris.Drugs. 1995 Sep;50(3):495-512. doi: 10.2165/00003495-199550030-00007. Drugs. 1995. PMID: 8521771 Review.
-
Optimal timing for antihypertensive dosing: focus on valsartan.Ther Clin Risk Manag. 2007 Mar;3(1):119-31. doi: 10.2147/tcrm.2007.3.1.119. Ther Clin Risk Manag. 2007. PMID: 18360620 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical